Pharmalittle: Biotechs worry about Democrats’ drug pricing bill; PhRMA criticizes four countries over policies

first_imgPharmalot Ed Silverman GET STARTED Log In | Learn More By Ed Silverman Nov. 12, 2019 Reprints STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Pharmalittle: Biotechs worry about Democrats’ drug pricing bill; PhRMA criticizes four countries over policies Alex Hogan/STAT @Pharmalot Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a decidedly cold wind blowing about the Pharmalot grounds. Our short person has successfully departed for another day of learning at the local schoolhouse and our official mascot is comfortably snoozing in a corner. This leaves us to focus on the task at hand, which is to forage for interesting items and the like. So time to get cracking. Here are a few tidbits to help on your own quest. Hope all goes well today.Small biotech companies — most of whom stick to science, not politics — are speaking up about the House Democrats’ drug pricing bill because they are uniquely worried that the policies included in the legislation bill will dry up venture capital funding that drives their industry, STAT writes. In turn, this would make it impossible for other small startups that turn basic research into new medicines to get off the ground. “This bill could have devastating effects on our industry, period. End of discussion,” says Paul Hastings of Nkarta Therapeutics.center_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Tags Congressdrug pricingpharmalittleSTAT+ [email protected] About the Author Reprints What’s included? What is it?last_img

Leave a Reply

Your email address will not be published. Required fields are marked *